Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection.
Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection.
复制标题
DOI：
10.3389/fimmu.2022.850987
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
Wilson JM
中科院分区：
文献类型：
--
作者：
Keshavarz B;Richards NE;Workman LJ;Patel J;Muehling LM;Canderan G;Murphy DD;Brovero SG;Ailsworth SM;Eschenbacher WH;McGowan EC;Mann BJ;Nelson MR;Kadl A;Woodfolk JA;Platts-Mills TAE;Wilson JM
三种新冠肺炎疫苗已获得美国食品和药物管理局的授权并在美国使用，但关于这些疫苗引发的免疫反应持久性的面对面数据有限。我们用定量方法研究了BNT162b2、mRNA-1273或Ad26.COV2.S在一名员工队列中激发的结合抗体，时间跨度长达10个月。探讨了年龄和性别作为反应修饰性因素。在234名受试者中，114人接种了BNT162b2,114人接种了mRNA1273，6人接种了Ad26.COV2.S。BNT162b2和mRNA127在第二次接种后7-20天检测到的免疫球蛋白水平与mRNA127相似，是Ad26.COV2.S的50倍。但在第21天和以后的时间点，BNT162b2诱导的免疫球蛋白水平低于mRNA1273。因此，BNT162b2的免疫球蛋白衰减曲线比mRNA1273更陡峭。在接受BNT162b2治疗的患者中，年龄是免疫球蛋白水平的显著影响因素，但不是mRNA1273。6个月后，与6个月前因新冠肺炎住院的患者相比，BNT162b2诱导的免疫球蛋白水平低于6个月前因新冠肺炎而住院的患者。将疫苗引发的抗体与针对季节性人类冠状病毒的稳态抗体进行比较时，也观察到了类似的发现。随着时间的推移，观察到BNT162b2和mRNA-1273在临床保护方面的差异，不同的免疫球蛋白衰减可能是原因之一。
Three COVID-19 vaccines have received FDA-authorization and are in use in the United States, but there is limited head-to-head data on the durability of the immune response elicited by these vaccines. Using a quantitative assay we studied binding IgG antibodies elicited by BNT162b2, mRNA-1273 or Ad26.COV2.S in an employee cohort over a span out to 10 months. Age and sex were explored as response modifiers. Of 234 subjects in the vaccine cohort, 114 received BNT162b2, 114 received mRNA-1273 and six received Ad26.COV2.S. IgG levels measured between seven to 20 days after the second vaccination were similar in recipients of BNT162b2 and mRNA-127 and were ~50-fold higher than in recipients of Ad26.COV2.S. However, by day 21 and at later time points IgG levels elicited by BNT162b2 were lower than mRNA-1273. Accordingly, the IgG decay curve was steeper for BNT162b2 than mRNA-1273. Age was a significant modifier of IgG levels in recipients of BNT162b2, but not mRNA-1273. After six months, IgG levels elicited by BNT162b2, but not mRNA-1273, were lower than IgG levels in patients who had been hospitalized with COVID-19 six months earlier. Similar findings were observed when comparing vaccine-elicited antibodies with steady-state IgG targeting seasonal human coronaviruses. Differential IgG decay could contribute to differences observed in clinical protection over time between BNT162b2 and mRNA-1273.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1016/s2213-2600(21)00407-0
发表时间：
2021-12
期刊：
The Lancet. Respiratory medicine
影响因子：
--
作者：
Milne G;Hames T;Scotton C;Gent N;Johnsen A;Anderson RM;Ward T
通讯作者：
Ward T
DOI：
10.1093/infdis/jiab593
发表时间：
2022-04-01
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
Naranbhai V;Garcia-Beltran WF;Chang CC;Berrios Mairena C;Thierauf JC;Kirkpatrick G;Onozato ML;Cheng J;St Denis KJ;Lam EC;Kaseke C;Tano-Menka R;Yang D;Pavlovic M;Yang W;Kui A;Miller TE;Astudillo MG;Cahill JE;Dighe AS;Gregory DJ;Poznansky MC;Gaiha GD;Balazs AB;Iafrate AJ
通讯作者：
Iafrate AJ
DOI：
10.15585/mmwr.mm7038e1
发表时间：
2021-09-24
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Self WH;Tenforde MW;Rhoads JP;Gaglani M;Ginde AA;Douin DJ;Olson SM;Talbot HK;Casey JD;Mohr NM;Zepeski A;McNeal T;Ghamande S;Gibbs KW;Files DC;Hager DN;Shehu A;Prekker ME;Erickson HL;Gong MN;Mohamed A;Henning DJ;Steingrub JS;Peltan ID;Brown SM;Martin ET;Monto AS;Khan A;Hough CL;Busse LW;Ten Lohuis CC;Duggal A;Wilson JG;Gordon AJ;Qadir N;Chang SY;Mallow C;Rivas C;Babcock HM;Kwon JH;Exline MC;Halasa N;Chappell JD;Lauring AS;Grijalva CG;Rice TW;Jones ID;Stubblefield WB;Baughman A;Womack KN;Lindsell CJ;Hart KW;Zhu Y;Mills L;Lester SN;Stumpf MM;Naioti EA;Kobayashi M;Verani JR;Thornburg NJ;Patel MM;IVY Network
通讯作者：
IVY Network
影响因子：
120.7
作者：
Stephenson, Kathryn E.;Le Gars, Mathieu;Barouch, Dan H.
通讯作者：
Barouch, Dan H.